Voquezna Dual Pak is used to treat an infection in the stomach caused by bacteria called Helicobacter pylori (H. pylori). It contains two different medicines that work together to kill this bacteria.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the prior approval supplement for Phathom Pharmaceutical’s reformulated vonoprazan ...

Phathom Pharmaceuticals (NASDAQ:PHAT) stock rose ~10% on Tuesday after the company said it expects to refile an application seeking approval of vonoprazan to treat erosive esophagitis in Q2 2023 ...

one with amoxicillin and clarithromycin (Voquezna Triple Pak), and one with amoxicillin (Voquezna Dual Pak), to treat Helicobacter pylori (H. pylori) infection in adults, drugmaker Phathom ...

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom ...

and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn ...

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom’s ...

the Takeda spinout won FDA approval for vonoprazan as a component in two combinations—Voquezna Dual Pak and Voquezna Triple Pak—to treat H. pylori infection. Shortly after those approvals ...

approved both VOQUEZNA™ TRIPLE PAK™ (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA™ DUAL PAK™ (vonoprazan tablets, amoxicillin capsules), for the treatment ...